Last edition
News about "first-in-class antibody program"
Boehringer Ingelheim Licenses Inflammation Antibody Program from Immunitas Therapeutics
Boehringer Ingelheim licenses a first-in-class antibody program from Immunitas Therapeutics to develop targeted therapies for chronic inflammatory diseases and expand its immunology pipeline.
First-in-class Antibody Program | 14/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members